VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the publication of a new feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built f ...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the publication of a new feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built f ...

- Patent-pending pre-scan technology enables custom radiation dose tailored to patient’s unique breast size and composition - - Feature aligns with personalized medicine trends driving the global breast imaging device market size to USD $8.69 billion by 2030 - - Integrated into the IzoView commercial model alongside modular engineering, compression-free imaging, and AI-driven image optimization - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corp ...

- Patent-pending pre-scan technology enables custom radiation dose tailored to patient’s unique breast size and composition - - Feature aligns with personalized medicine trends driving the global breast imaging device market size to USD $8.69 billion by 2030 - - Integrated into the IzoView commercial model alongside modular engineering, compression-free imaging, and AI-driven image optimization - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corp ...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of a new Frequently Asked Questions (“FAQ”) page on its corporate website. The new FAQ resource, available at www.izocorp.c ...

公司核心技术与产品 - Izotropic公司专注于商业化IzoView Breast CT成像系统 该系统旨在通过更精确的筛查、诊断和治疗手段改善乳腺癌检测效果 [2][3] - 该技术可检测小至2毫米的癌症病灶 而当前标准护理的平均检测尺寸为11毫米 意味着可提前12至18个月发现癌症 [4] - 公司近期宣布开发出独有的AI技术能力 该技术预计将随时间推移获得市场认可 [5] 商业化战略与市场定位 - 商业化策略分阶段在欧洲和美国推进 初期重点面向医院、医疗机构和影像诊所销售设备 [6] - 欧美市场合计占全球该类设备市场份额近50% [6] - 公司认为其可能成为大型企业的收购目标 因后者若希望维持市场份额需通过收购介入该领域 [5] 知识产权与竞争优势 - 公司通过专利组合、商业秘密和产品构建知识产权保护体系 [5] - 技术优势体现在对早期侵袭性癌症的检测能力上 当前标准护理在该领域存在显著不足 [4] 监管进展与市场机会 - 产品开发符合FDA标准 若获得FDA批准将打开全球市场机会 [3][6] - 目前正通过临床验证支持商业化进程 并已观察到显著早期需求 [5]

核心观点 - 公司获得美国唯一针对乳腺CT计算机辅助诊断(CADx)的专利保护 并拥有该技术及乳腺CT的全球独家授权 [1] - CADx功能将作为上市后软件升级集成到旗舰产品IzoView乳腺CT成像系统中 可能作为早期用户激励措施 [1][5] 专利与技术优势 - 公司通过全球独家授权协议持有乳腺CT技术及相关CADx专利的专有权 [1] - CADx是基于人工智能的放射学软件工具 通过分析医学影像评估恶性肿瘤可能性 支持医生决策 [2] - 该技术旨在解决传统成像方式(如乳腺X线摄影、数字乳腺断层合成、超声)因组织重叠、乳腺密度或操作差异导致的漏诊问题 [2] - 在MRI和乳腺CT应用中 CADx可对检查进行分诊、突出异常区域并减少阅片时间 提高诊断一致性和工作效率 [2] 产品定位与特性 - IzoView乳腺CT成像系统是真正的专用3D乳腺成像替代方案 填补了DBT和MRI之间的技术空白 [3] - 初始适应症为使用对比剂增强 对致密乳腺组织无症状患者进行辅助性乳腺癌筛查 [3] - 初始上市版本将集成专有的机器学习图像重建算法 优化图像质量同时保持与双视图乳腺X线摄影相当的低辐射剂量 [4] 商业化策略 - CADx功能将在获得额外市场授权后通过软件升级提供 创造未来软件收入机会 [5] - 该功能可能作为早期用户激励措施 既支持临床价值又贡献收入增长 [5]

  - Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT - - Trained on 15 years of specialized breast CT data and protected as a trade secret, giving Izotropic a durable competitive edge - - AI enhances IzoView’s image quality by reducing CT image noise without increasing radiation dose - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) ( ...

- Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT - - Trained on 15 years of specialized breast CT data and protected as a trade secret, giving Izotropic a durable competitive edge - - AI enhances IzoView’s image quality by reducing CT image noise without increasing radiation dose - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (F ...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of BreastCT.com, a new online platform supporting the Company's awareness initiatives. BreastCT.com has been created as a c ...